Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses.
The use of biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres as a cancer vaccine delivery system for induction of anti-idiotypic responses has been investigated using a single chain antibody scFv-pDL10, which recognizes the human ovarian cancer antigen CA125. Immunization of mice with scFv-pDL10 encapsulated in PLGA microspheres resulted in enhanced humoral and cellular immune responses when compared to scFv-pDL10 alone. Induced anti-idiotypic antibodies (Ab2) which mimic the original antigen CA125 compete with CA125 for the epitope. A cellular response (T2 induction) was also observed. These results raise the possibility of anti-idiotypic antibody induction by a single chain antibody, encapsulated in biodegradeble microspheres, as a potential vaccine for ovarian carcinoma.
Ma
J
J
Research and Development, AltaRex Corp., 300, 8625-112 Street, Edmonton, Alberta, Canada. jma@gpu.srv.ualberta.ca
Luo
D
D
Kwon
G S
GS
Samuel
J
J
Noujaim
A A
AA
Madiyalakan
R
R
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D018394:CA-125 Antigen / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D019344:Lactic Acid; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers
D000888:Antibodies, Anti-Idiotypic; D018394:CA-125 Antigen; D019496:Cancer Vaccines; D004337:Drug Carriers; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid